EKSO — Ekso Bionics Holdings, Inc.

Ekso Bionics Q2 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $2.1 million, down from $5 million in Q2 2024, attributed to delays in multi-device Enterprise Health sales, partially offset by increased sales of the Ekso Indego Personal device.
• Gross Profit: $800,000 with a gross margin of approximately 40%, down from $2.6 million and 53% in Q2 2024.
• Operating Expenses: $4.8 million, a slight decrease from $5 million in Q2 2024.
• Net Loss: $2.7 million or $1.24 per share, compared to a net loss of $2.4 million or $1.99 per share in the prior year.
• Cash Position: $5.2 million in cash and restricted cash as of June 30, 2025.

2. Strategic Updates and Business Highlights

• Product Focus: Ekso Bionics continues to develop exoskeleton products for healthcare, focusing on rehabilitation and mobility for individuals with physical disabilities.
• Growth Initiatives:
  • Launched eksoUniversity, a virtual platform for continuing education aimed at physical therapists, to enhance awareness and adoption of exoskeleton technology.
  • Engaged PRIA Healthcare to aid in market access and reimbursement processes for the Ekso Indego Personal device.
  • Established partnerships with distributors, including National Seating & Mobility and Bionic P&O, to expand market reach.
• AI Integration: Joined the NVIDIA Connect program to leverage AI for enhancing product capabilities, including the development of an AI voice agent for the EksoNR device.

3. Forward Guidance and Outlook

• Management remains optimistic about closing deferred Enterprise Health sales, with expectations to recover some revenue in the second half of 2025.
• Anticipates that Personal Health product revenues will grow significantly, potentially contributing 25% of total revenue in 2025, with expectations to overtake Enterprise Health revenues by 2027.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The significant drop in revenue compared to the previous year raises concerns about sales execution and market conditions.
• Regulatory and Economic Headwinds: Some customers have delayed purchases due to loss of federal grants and economic uncertainties, impacting sales forecasts.
• Dependence on Federal Grants: Approximately 10% of Enterprise customers rely on federal grants, creating vulnerability in sales if these grants are not renewed.

5. Notable Q&A Insights

• Deferred Sales: Management confirmed approximately $1.4 million in deferred sales from Q2, with expectations to close these deals in Q3.
• Growth Projections: The transition of Personal Health revenues to potentially surpass Enterprise Health revenues is projected to occur within 18 months to 2 years.
• Market Access Challenges: Ongoing efforts to navigate the complexities of reimbursement processes are critical, with some positive outcomes noted in recent appeals.
• Future Course Offerings: EksoUniversity will expand beyond exoskeletons to cover broader neuro rehabilitation topics, leveraging contributions from a network of neuro physical therapists.

In summary, while Ekso Bionics faced a challenging second quarter with declining revenues and operational setbacks, management is focused on strategic initiatives to enhance product offerings and market penetration, particularly in the Personal Health segment. The outlook remains cautiously optimistic as the company works to recover from recent challenges.